BioCardia, Inc. has announced its financial results for the third quarter of 2026, marking a significant moment for the company as it continues to develop innovative therapies for cardiovascular and pulmonary diseases. The report, filed on November 12, 2026, showcases the company's progress in its CardiAMP autologous cell therapy and Helix delivery system, which are poised to make a substantial impact in the biological products sector.
BioCardia, Inc. operates within the biological products industry (SIC 2836) and is listed on the Nasdaq under the ticker BCDA. The company has a history of changing its name, previously known as Tiger X Medical, Inc. and Cardo Medical, Inc. The latest filing is part of a series of recent disclosures that include a quarterly report on Form 10-Q and other updates.
In the filing, BioCardia detailed its financial performance for the quarter ended September 30, 2026. The company issued a press release highlighting its achievements and future plans. According to the filing, "On November 12, 2026, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report." This release emphasizes BioCardia's commitment to advancing its CardiAMP therapy and Helix delivery system.
The impact of these developments may extend to various stakeholders, including investors, healthcare providers, and patients seeking innovative treatments for heart failure and other conditions. BioCardia's advancements in cell therapy and delivery systems could influence the competitive landscape within the biological products industry, prompting other companies to enhance their offerings.
Looking ahead, BioCardia has indicated that it plans to hold a conference call to discuss its business highlights further. This call is scheduled for 4:30 PM ET on the same day the results were announced, allowing stakeholders to engage directly with the company's management and gain insights into future strategies. The filing does not specify what happens next beyond this call, but the company's ongoing initiatives suggest a proactive approach to regulatory approvals and clinical trials.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










